BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced a clinical trial assessing the capacity of its red grape cell (RGC) composition to promote eye health in a collaboration with the International Neurorehabilitation Institute (INI) in Lutherville, Maryland.
Led by Dr Daniel Becker, Director of the INI and Assistant Professor of Neurology at Johns Hopkins School of Medicine, the study will evaluate the impact of RGC on multiple sclerosis (MS)-related optic neuritis driven by inflammation. The study aims to elucidate the mechanisms through which RGC impacts the disease by measuring anti-oxidative, detoxifying, and inflammatory biomarkers.
RGC is a patented composition based on BioHarvest's Botanical-Synthesis technology, with consistency and quality that have the potential to meet the criteria for being used as an Active Pharmaceutical Ingredient (API).
READ: BioHarvest Sciences reports 2022 sales orders of US$6.1M, 2.6 times higher than 2021
"To date there are no medications that can help improve vision after an acute optic neuritis event. This exciting research will help us understand if phytonutrients are capable of affecting the inflammatory environment as well as the neuro-regenerative capacity within the injured central nervous system," said Dr Becker in a statement.
The research team hypothesizes that RGC will result in improvements to eye health by modulating a variety of biomarkers compared to baseline in the study participants. The next important step for this study is submission to an Institutional Review Board (IRB) to be followed by the study launch with 15-30 participants.
"This is the first human clinical study to evaluate the combination of health-promoting phytonutrients as found in RGC for the promotion of eye health," said BioHarvest chief medical officer Dr Brian Cornblatt, co-investigator of the study.
"Considering many people with MS take biologics which have immunosuppressing properties, adding high-dose steroids is not ideal in the current environment, with a pandemic and influenza on the rise globally. We need to go back to medicine's roots, literally, and study safe, effective, and affordable phytonutrients derived from plants."
The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS, and some 200 new cases are diagnosed weekly in the US alone. While the root causes of MS are still unknown, there are definite links between genetic and select environmental factors.
"We are inspired by nature and driven by science. Clinical studies are an important pillar in building a company that creates products that are both trusted and effective for our customers," said BioHarvest CEO Ilan Sobel.
"As a biotech company dedicated to health and wellness, we plan to extend our Botanical-Synthesis technology into the pharmaceutical industry. This collaboration with such a reputable North American research partner marks an important step to create additional science-based therapeutic solutions that provide better treatment options."
Canada-listed BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture.
Contact the author at jon.hopkins@proactiveinvestors.com